Prostatype Interim Analysis Demonstrates Ability to Alter Patient Management and Predict Disease Progression

Prostatype Genomics in collaboration with seven prominent Spanish hospitals and the Spanish National Association of Urology is conducting a retrospective multicenter study involving 160 patients to assess its prostate cancer prognostic Prostatype®. An interim analysis of this study unveiled evidence suggesting that Prostatype® offers clinical insight and the ability to alter treatment plans for patients initially classified as low or intermediate risk for prostate cancer. The test will compete against established prostate cancer prognostic tests from companies such as Myriad Genetics, Veracyte, and MDx Health that are standard of care for prostate cancer decision making in the United States.

The interim analysis shows treatment plans would have been modified in up to 60% of cases if the test had been integrated into the diagnostic process from the outset. Furthermore, the data demonstrates Prostatype® can predict disease progression, distinguishing individuals who require curative treatment immediately upon diagnosis from those who may benefit from active monitoring, sparing them from unnecessary aggressive interventions. Additionally, the interim analysis validates Prostatype® as a tool to identify those low-risk prostate cancer patients for whom delaying curative treatment might be a safe and appropriate strategy.

The Prostatype® Test System combines gene expression data with traditional clinical parameters, such as PSA, Gleason Score, and Tumor Stage, to calculate a P-score. Prostatype Genomics has identified three significant stem cell genes—IGFBP3, F3, and VGLL3—that exhibit correlations with overall and prostate cancer-specific survival. Importantly, the Prostatype® test is conducted using existing biopsy samples obtained during diagnosis. By quantifying the RNA expression levels of these stem cell genes in the patient’s tumor, the Prostatype® system offers insight into the cancer’s genetic fingerprint.

Fredrik Persson, the CEO of Prostatype Genomics, commented on the significant strides they are making in this space: “The multicenter study we are conducting in collaboration with seven leading Spanish hospitals reaffirms what external studies have previously demonstrated and further solidifies Prostatype® as a formidable prognostic tool. Its clinical implementation is poised to deliver remarkable benefits for patients, healthcare providers, and those responsible for healthcare costs. Our choice to conduct this study in Spain was strategic, as we recognized the Spanish market as a priority pilot market. With a robust local partner in Eurofins Megalab, this study will be a cornerstone for our continued expansion in Spain.”